Kyprolis(carfilzmomib) launched in late July 2012, net sales for the second quarter of 2013 were $61.0 million according to Onyx announcement.
Onyx want Patrys to initiate an Investigator-Sponsored Clincal Trial using PAT-SM6 in combination with Onyx Pharmaceuticals' carfilzomib
BECAUSE:
"In June 2013 an article in respect of the preclinical studies and phase I clinical trial conducted with PAT-SM6 on melanoma was published. The results of preclinical studies conducted in melanoma confirm that PAT-SM6 induces tumour cell death by interacting with GRP78 and LDL. Additional preclinical data in an aggressive and metastatic mouse model showed PAT-SM6 significantly suppressed or eliminated the development of secondary tumours in all treated mice. Furthermore, PAT-SM6 was safe and well tolerated in animal toxicology studies. The publication also includes an overview of the Phase I clinical trial in patients with melanoma which was completed in February 2012 meeting its primary endpoint of safety and showing early evidence that PAT-SM6 specifically targets melanoma tumours and causes cell death."
- Forums
- ASX - By Stock
- PAB
- how low tomorrow
how low tomorrow, page-14
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $589 | 91.50K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 4759154 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1636778 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 4759154 | 0.006 |
13 | 6829276 | 0.005 |
7 | 4425000 | 0.004 |
4 | 2729016 | 0.003 |
2 | 4520000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1636778 | 2 |
0.008 | 4991280 | 4 |
0.010 | 1592000 | 4 |
0.011 | 1080000 | 2 |
0.012 | 552407 | 4 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |